Bristol Myers Squibb has received FDA approval for Opdivo intravenous injection in combination with fluoropyrimidine and platinum-containing chemotherapy. The drug is intended to treat patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma regardless of PD-L1 expression status.